Free Trial

ProPhase Labs (PRPH) Competitors

ProPhase Labs logo
$0.43 +0.00 (+0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$0.41 -0.01 (-2.87%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRPH vs. GNTA, VNRX, ANEB, PYXS, ADAP, PYRGF, VRCA, CNTB, STRO, and IKNA

Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Genenta Science (GNTA), VolitionRx (VNRX), Anebulo Pharmaceuticals (ANEB), Pyxis Oncology (PYXS), Adaptimmune Therapeutics (ADAP), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Connect Biopharma (CNTB), Sutro Biopharma (STRO), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry.

ProPhase Labs vs. Its Competitors

Genenta Science (NASDAQ:GNTA) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Genenta Science's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
ProPhase Labs N/A -184.38%-64.59%

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Genenta Science had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 2 mentions for Genenta Science and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 1.87 beat Genenta Science's score of 1.23 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company Overall Sentiment
Genenta Science Positive
ProPhase Labs Very Positive

Genenta Science has higher earnings, but lower revenue than ProPhase Labs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$9.64MN/AN/A
ProPhase Labs$5.85M3.02-$53.36M-$1.26-0.34

Genenta Science presently has a consensus target price of $25.00, indicating a potential upside of 561.38%. Given Genenta Science's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genenta Science is more favorable than ProPhase Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
ProPhase Labs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Genenta Science has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.41, suggesting that its stock price is 141% less volatile than the S&P 500.

Summary

Genenta Science beats ProPhase Labs on 10 of the 12 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRPH vs. The Competition

MetricProPhase LabsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$17.66M$2.42B$5.53B$9.13B
Dividend YieldN/A1.81%5.06%4.01%
P/E Ratio-0.349.2128.5819.57
Price / Sales3.02461.46372.6479.65
Price / CashN/A22.3424.7227.51
Price / Book1.704.708.235.56
Net Income-$53.36M$30.99M$3.19B$252.37M
7 Day Performance-3.82%7.04%5.46%3.11%
1 Month Performance28.34%22.46%9.39%11.74%
1 Year Performance-87.10%-2.80%30.48%17.41%

ProPhase Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRPH
ProPhase Labs
0.5408 of 5 stars
$0.43
+0.4%
N/A-87.1%$17.66M$5.85M-0.34130Positive News
GNTA
Genenta Science
2.6317 of 5 stars
$3.98
+4.7%
$25.00
+528.1%
+19.3%$69.50MN/A0.007Gap Up
VNRX
VolitionRx
2.1303 of 5 stars
$0.67
-9.0%
$3.50
+419.8%
+1.3%$69.38M$1.31M-1.8780
ANEB
Anebulo Pharmaceuticals
2.7312 of 5 stars
$1.65
-2.1%
$5.50
+234.3%
-32.8%$69.02MN/A-6.334High Trading Volume
PYXS
Pyxis Oncology
2.306 of 5 stars
$1.14
+3.6%
$9.00
+689.5%
-63.2%$68.14MN/A-0.7260
ADAP
Adaptimmune Therapeutics
1.9764 of 5 stars
$0.24
-3.6%
$1.35
+460.6%
-79.0%$66.26M$178.03M-0.89490
PYRGF
PyroGenesis Canada
0.0896 of 5 stars
$0.35
+4.0%
N/A-54.8%$66.16M$9.14M-5.9190
VRCA
Verrica Pharmaceuticals
4.4943 of 5 stars
$0.83
+17.4%
$8.00
+863.9%
-90.5%$65.36M$7.57M-0.6940Gap Down
CNTB
Connect Biopharma
3.1195 of 5 stars
$1.14
-2.5%
$7.00
+514.0%
+21.6%$64.97M$26.03M0.00110
STRO
Sutro Biopharma
4.3 of 5 stars
$0.74
-2.9%
$6.11
+725.4%
-81.7%$64.46M$62.04M-0.25240
IKNA
Ikena Oncology
2.7855 of 5 stars
$1.35
+1.5%
$3.00
+122.2%
-19.3%$64.18M$9.16M-1.5770Gap Up

Related Companies and Tools


This page (NASDAQ:PRPH) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners